150 mg open-label secukinumab + 150 mg double-blinded secukinumab + 300 mg double-blinded secukinumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ankylosing Spondylitis
Conditions
Ankylosing Spondylitis
Trial Timeline
Mar 13, 2018 → May 29, 2021
NCT ID
NCT03350815About 150 mg open-label secukinumab + 150 mg double-blinded secukinumab + 300 mg double-blinded secukinumab
150 mg open-label secukinumab + 150 mg double-blinded secukinumab + 300 mg double-blinded secukinumab is a approved stage product being developed by Novartis for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03350815. Target conditions include Ankylosing Spondylitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03350815 | Approved | Completed |
Competing Products
20 competing products in Ankylosing Spondylitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab | Celltrion | Phase 1 | 33 |
| Infliximab | Celltrion | Phase 1 | 33 |
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| adalimumab | Eisai | Phase 3 | 77 |
| Ixekizumab + Placebo + Adalimumab | Eli Lilly | Phase 3 | 77 |
| Tramadol /acetaminophen + Diclofenac | Johnson & Johnson | Approved | 85 |
| Golimumab + Placebo | Johnson & Johnson | Phase 3 | 77 |
| Golimumab | Johnson & Johnson | Approved | 85 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 2/3 | 65 |
| placebo for risankizumab + risankizumab | AbbVie | Phase 2 | 52 |
| Adalimumab | AbbVie | Approved | 85 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 52 |
| Adalimumab | AbbVie | Pre-clinical | 23 |
| infliximab + Placebo | Merck | Phase 3 | 77 |
| Infliximab | Merck | Approved | 85 |
| Infliximab + Placebo + Naproxen | Merck | Phase 3 | 77 |
| Infliximab | Merck | Pre-clinical | 23 |
| Golimumab | Merck | Approved | 85 |
| Remicade | Merck | Approved | 85 |
| Remicade | Merck | Approved | 85 |